Rubicon Research Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
RUBICON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Rubicon Research Limited reported strong full-year FY26 consolidated results with revenue from operations of ₹17,539.56 million, up 36.6% year-on-year from ₹12,842.72 million in FY25. Net profit after tax stood at ₹2,467.35 million, surge of 83.6% compared to ₹1,343.61 million in the prior year. Q4 PAT was ₹767.85 million versus ₹362.45 million in Q4 FY25, more than doubling. The company completed its IPO in October 2025 raising ₹5,000 million through a fresh issue and used ₹2,646.41 million to prepay debt. Post-IPO, equity more than doubled to ₹12,888.23 million. The Board recommended a dividend of ₹1.50 per equity share. Auditors Deloitte Haskins & Sells LLP issued an unmodified opinion. Subsequently, the company acquired 65% stake in Mono Lifesciences Limited for ₹1,759.17 million in April 2026.
Strong financial performance with near-doubling of PAT and healthy revenue growth of 36.6%. IPO proceeds have strengthened the balance sheet significantly. The dividend recommendation signals confidence in cash generation. No audit qualifications indicate clean financials.